Despite being the world’s first approved vaccine against respiratory syncytial virus infection, GSK expects a slower initial rollout for Arexvy, CEO Emma Walmsley said during a second-quarter earnings briefing Wednesday, as reported by Reuters.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,